Risk of cervical pre-cancer and cancer in women with multiple sclerosis exposed to high efficacy disease modifying therapies

Francesca Bridge; Francesca Bridge; Julia M. L. Brotherton; Julia M. L. Brotherton; Yi Foong; Yi Foong; Yi Foong; Helmut Butzkueven; Helmut Butzkueven; Vilija G. Jokubaitis; Vilija G. Jokubaitis; Anneke Van der Walt; Anneke Van der Walt

doi:10.3389/fneur.2023.1119660

Frontiers in Neurology (Feb 2023)

Risk of cervical pre-cancer and cancer in women with multiple sclerosis exposed to high efficacy disease modifying therapies

Francesca Bridge,
Francesca Bridge,
Julia M. L. Brotherton,
Julia M. L. Brotherton,
Yi Foong,
Yi Foong,
Yi Foong,
Helmut Butzkueven,
Helmut Butzkueven,
Vilija G. Jokubaitis,
Vilija G. Jokubaitis,
Anneke Van der Walt,
Anneke Van der Walt

Affiliations

Francesca Bridge: Department of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC, Australia
Francesca Bridge: Department of Neurology, Alfred Health, Melbourne, VIC, Australia
Julia M. L. Brotherton: Australian Centre for the Prevention of Cervical Cancer (Formerly Victorian Cytology Service), Carlton South, VIC, Australia
Julia M. L. Brotherton: Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, VIC, Australia
Yi Foong: Department of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC, Australia
Yi Foong: Department of Neurology, Alfred Health, Melbourne, VIC, Australia
Yi Foong: Department of Neurosciences, Eastern Health, Melbourne, VIC, Australia
Helmut Butzkueven: Department of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC, Australia
Helmut Butzkueven: Department of Neurology, Alfred Health, Melbourne, VIC, Australia
Vilija G. Jokubaitis: Department of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC, Australia
Vilija G. Jokubaitis: Department of Neurology, Alfred Health, Melbourne, VIC, Australia
Anneke Van der Walt: Department of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC, Australia
Anneke Van der Walt: Department of Neurology, Alfred Health, Melbourne, VIC, Australia

DOI: https://doi.org/10.3389/fneur.2023.1119660
Journal volume & issue: Vol. 14

Abstract

Read online

There is a growing need to better understand the risk of malignancy in the multiple sclerosis (MS) population, particularly given the relatively recent and widespread introduction of immunomodulating disease modifying therapies (DMTs). Multiple sclerosis disproportionately affects women, and the risk of gynecological malignancies, specifically cervical pre-cancer and cancer, are of particular concern. The causal relationship between persistent human papillomavirus (HPV) infection and cervical cancer has been definitively established. To date, there is limited data on the effect of MS DMTs on the risk of persistent HPV infection and subsequent progression to cervical pre-cancer and cancer. This review evaluates the risk of cervical pre-cancer and cancer in women with MS, including the risk conferred by DMTs. We examine additional factors, specific to the MS population, that alter the risk of developing cervical cancer including participation in HPV vaccination and cervical screening programs.

Published in Frontiers in Neurology

ISSN: 1664-2295 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neurosciences. Biological psychiatry. Neuropsychiatry: Neurology. Diseases of the nervous system
Website: https://www.frontiersin.org/journals/neurology/

About the journal

Abstract

Keywords